Pfizer’s second dose of the Covid-19 vaccine delayed the elderly at risk of a South African corona virus variant. A single dose of the vaccine cannot produce a strong enough immune response to kill a new type of virus. Health officials have emphasized that those who have been given only the first vaccine should be cautious as there cannot be a complete guarantee of safety till the second dose.
Research has shown that Pfizer’s delay in the second dose of the Covid-19 vaccine may leave some elderly patients vulnerable to the South African corona virus variant. Lab research by scientists at Cambridge University saw that the first dose of Pfizer’s vaccine may not be enough to fight mutations.
South African variant of Corona virus will not provide protection
Researchers say that a single dose of vaccine cannot produce strong enough immune response to kill a new type of virus. Antibody levels appear to be protective only, but researchers believe that the vaccine is still likely to be ‘less effective’ on the South African variant. According to research, only after the second dose, people above the age of 80 years will get strong immune response.
Researchers said that 9.3 million people who had received the first dose are still at risk of corona virus infection within three months before taking the second dose. Health officials have emphasized that those who have been given only the first vaccine should be cautious as there cannot be a complete guarantee of safety till the second dose.
Pfizer’s Covid Vaccine Single Dose Does Not Protect Elderly
Research has revealed that the new variety of corona virus contains E484K, which increases the amount of antibodies required to kill the corona virus. The E484K mutation features new variants of South African and Brazil. Blood samples of 26 people were taken by Cambridge researchers, 15 of them over the age of 80 had taken the first dose of Pfizer.
His blood contained antibodies made to fight the corona virus through the immune system, through natural infection or by vaccination. They tested the blood sample against the synthetic version of the British and South African variants and monitored their antibody response.
The results showed that the antibodies in all the volunteers were sufficient to kill the British variant. But when the E484K mutation was added, 10 times more antibodies than the ‘original’ Covid strain were needed to eliminate the corona virus.
Researchers told that the antibodies level of seven people was so low that the virus could not be killed after the first dose and all these people were more than 80 years of age. Three weeks after the second dose, his antibody level reached the level that killed the virus. Researcher Ravi Gupta said, “Our work suggests that the vaccine may be less effective in handling E484K mutations.” Responding to the discovery, the scientists said that now is the ‘right time for Britain to break away from a dose strategy’.
Nidhi Malviya is fun loving girl. She writes at NoobFeeds about various topics related to Finance, Technology, Business etc.